Overview

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

Status:
Completed

Trial end date:
2017-01-24

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Benralizumab
Vaccines